β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment

JP Sommadossi, A Moussa - US Patent 9,828,410, 2017 - Google Patents
7, 211, 570 B2 7, 268, 119 B2 7, 285, 658 B2 7, 307, 065 B2 7, 323, 449 B2 7, 339, 054 B2
7, 365, 057 B2 7, 384, 924 B2 7, 388, 002 B2 7, 429, 571 B2 7, 429, 572 B2 7, 456, 155 B2 …

Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus

A Moussa, JP Sommadossi - US Patent 10,519,186, 2019 - Google Patents
US10519186B2 - Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus - Google
Patents US10519186B2 - Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus …

Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus

A Moussa, JP Sommadossi - US Patent 10,906,928, 2021 - Google Patents
6/2005 Watanabe et al. 7/2005 Sommadossi et al. 9/2005 Otto et al. 8/2006 Watanabe et al.
9/2006 Sommadossi et al. 9/2006 Carroll et al. 11/2006 Gosselin et al. 5/2007 Schinazi et al …

β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment

JP Sommadossi, A Moussa - US Patent 10,000,523, 2018 - Google Patents
5977061 A 11/1999 Holy et al. 6.348. 587 B1 2/2002 Schinazi et al. 6,660,721 B2 12/2003
Devos et al. 6, 777395 B2 8/2004 Bhat et al. 6,784, 166 B2 8/2004 Devos et al. 6,812.219 …

β-D-2′-deoxy-2′-α-fluoro-2′ β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment

JP Sommadossi, A Moussa - US Patent 10,005,811, 2018 - Google Patents
7, 138, 376 B2 11/2006 Gosselin et al. 7, 148, 206 B2 12/2006 Sommadossi et al. 7, 157,
441 B2 1/2007 Sommadossi et al. 7, 163, 929 B2 1/2007 Sommadossi et al. 7, 169, 766 B2 …

Beta-D-2′-deoxy-2′-alpha-fluoro-2′-beta-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment

JP Sommadossi, A Moussa - US Patent 10,239,911, 2019 - Google Patents
6, 949, 522 B2 7, 094, 770 B2 7, 105, 493 B2 7, 105, 499 B2 7, 125, 855 B2 7, 138, 376 B2
7, 148, 206 B2 7, 157, 441 B2 7, 163, 929 B2 7, 169, 766 B2 7, 192, 936 B2 7, 202, 224 B2 …

Zidovudine: Structural Modifications and their impact on biological activities and pharmacokinetic properties

NUA Mohsin, M Ahmed, M Irfan - Journal of the Chilean Chemical …, 2019 - SciELO Chile
Zidovudine was the first drug approved for the treatment of Acquired Immuno Deficiency
Syndrome (AIDS). Its chemical name is azidothymidine (AZT). AZT use is associated with …

Highly active compounds against COVID-19

JP Sommadossi, A Moussa - US Patent 10,874,687, 2020 - Google Patents
The present invention is the use of a small group of purine nucleotide phosphoramidate
disclosed herein or a pharma ceutically acceptable salt thereof in an effective amount for the …

β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment

JP Sommadossi, A Moussa - US Patent 10,815,266, 2020 - Google Patents
7/2005 Sommadossi et al. 9/2005 Otto et al. 8/2006 Watanabe et al. 9/2006 Sommadossi et
al. 9/2006 Carroll et al. 10/2006 Bhat et al. 11/2006 Gosselin et al. 12/2006 Sommadossi et …

β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment

J Sommadossi, A Moussa - US Patent 10,870,672, 2020 - Google Patents
8/2004 Bhat et al. 8/2004 Devos et al. 11/2004 LaColla et al. 6/2005 Watanabe et al. 6/2005
Schinazi et al. 7/2005 Sommadossi et al. 9/2005 Otto et al. 8/2006 Watanabe et al. 9/2006 …